Kidney & Urinary Health TCM | Dr. Chen Yiping (TCM Nephrology) | CMCS Shanghai

About Dr. Chen Yiping

Dr. Chen Yiping is a senior nephrologist at Longhua Hospital, affiliated with Shanghai University of Traditional Chinese Medicine — one of China's foremost centres for integrative renal medicine and a national reference institution for the TCM management of chronic kidney disease, diabetic nephropathy, and proteinuria. She is recognised for her expertise in slowing CKD progression through individualised herbal protocols, dietary guidance, and the precise integration of classical TCM nephrology with modern renal pharmacotherapy. Dr. Chen is a preferred specialist for international patients seeking non-dialysis kidney preservation strategies — patients who have been told that dialysis is inevitable and who are seeking a rigorous, evidence-informed approach to preserving residual renal function for as long as possible. Her clinical philosophy holds that CKD progression is not a fixed biological inevitability but a modifiable process — that the rate of eGFR decline can be meaningfully slowed by simultaneously optimising haemodynamic control, reducing proteinuria, resolving the Damp-turbidity and Blood stasis that obstruct the renal microvasculature in TCM terms, and correcting the Spleen-Kidney deficiency that underlies the constitutional vulnerability to progressive renal injury. Her department at Longhua Hospital has established one of Shanghai's most comprehensive integrative nephrology programmes, combining classical herbal prescription, acupuncture, structured renal dietary therapy, and optimised Western pharmacotherapy into a unified care pathway for patients with CKD Stages 3–5 and diabetic nephropathy.

Case Overview

Mr. David Carmichael (pseudonym), a 55-year-old Australian retired engineer based in Shanghai, presented with a seven-year history of type 2 diabetes and a three-year history of progressive diabetic nephropathy — CKD Stage 3b (eGFR 38 mL/min/1.73m²), persistent proteinuria (urine protein-to-creatinine ratio 850 mg/g), and poorly controlled blood pressure despite dual antihypertensive therapy. He had been advised by his nephrologist in Australia that dialysis was likely within three to five years if the current trajectory continued. TCM diagnosis identified Kidney and Spleen Qi-Yin Deficiency with Damp-Turbidity and Blood Stasis Obstructing the Kidney. Dr. Chen Yiping designed an integrative programme combining optimised Western renal pharmacotherapy (RAAS blockade intensification, SGLT2 inhibitor addition) with classical herbal prescription (Shenqi Dihuang Tang, modified with Damp-resolving and Blood-activating additions), acupuncture, and structured renal dietary therapy. At twelve-month follow-up, eGFR had stabilised at 41 mL/min/1.73m² (improvement from 38), proteinuria had reduced to 320 mg/g, and blood pressure was consistently at target. At three-year follow-up, the patient remained dialysis-free with eGFR 36 mL/min/1.73m² — a trajectory of decline significantly slower than projected at presentation.

Patient Background

• Name / Nationality: Mr. David Carmichael (pseudonym) — Australian; 55-year-old retired engineer based in Shanghai
• Age / Sex: 55-year-old male
• Chief Complaint: Progressive renal function decline with persistent proteinuria and poorly controlled blood pressure; seeking non-dialysis kidney preservation strategies
• Diabetes history: Type 2 diabetes diagnosed seven years prior; on metformin and sitagliptin; HbA1c 7.8% at presentation — suboptimal glycaemic control
• Renal history: Diabetic nephropathy diagnosed three years prior; eGFR declining from 58 mL/min/1.73m² at diagnosis to 38 mL/min/1.73m² at presentation — a decline of 20 mL/min over three years; persistent proteinuria despite losartan 100 mg daily; blood pressure 148/92 mmHg on losartan and amlodipine
• Past medical history: Hypertension for ten years; dyslipidaemia on atorvastatin; no prior renal replacement therapy; no drug allergies
• TCM four examinations:
  • Inspection: Pale, slightly puffy complexion; mild periorbital oedema; slightly overweight build; pale, enlarged tongue with tooth marks on lateral borders; thin white greasy coating with slight rootlessness in the centre
  • Auscultation/olfaction: Low voice; slightly short breath; no abnormal odour
  • Inquiry: Fatigue and lower limb heaviness; lumbar soreness; nocturia 2–3 times; reduced appetite; loose stools; mild lower limb oedema by evening; occasional dizziness on standing
  • Palpation: Deep, thready, slightly choppy pulse (沉细微涩脉)

Diagnostic Workup

Renal Function Panel

• eGFR 38 mL/min/1.73m² (CKD Stage 3b); serum creatinine 168 μmol/L; BUN 12.4 mmol/L; serum uric acid 468 μmol/L (elevated)

Urine Studies

• Urine protein-to-creatinine ratio (UPCR) 850 mg/g — significant proteinuria; urine albumin-to-creatinine ratio (UACR) 620 mg/g — macroalbuminuria; no haematuria

Glycaemic and Metabolic Panel

• HbA1c 7.8%; fasting glucose 9.2 mmol/L; total cholesterol 5.8 mmol/L; LDL-C 3.4 mmol/L; triglycerides 2.6 mmol/L

Renal Ultrasound

• Bilateral kidneys mildly reduced in size; increased cortical echogenicity bilaterally — consistent with diabetic nephropathy; no obstruction or masses

24-Hour Ambulatory Blood Pressure

• Mean blood pressure 146/90 mmHg; non-dipper pattern — nocturnal dipping less than 10%

Dr. Chen's pre-treatment assessment: The trajectory is the most important number in this consultation — not the current eGFR, but the rate of decline. This patient has lost 20 mL/min of eGFR in three years. If that rate continues, he will reach dialysis threshold within three to four years. The question is whether we can change that trajectory. The proteinuria at 850 mg/g is the primary driver of the progression — proteinuria is not just a marker of renal injury, it is a cause of it; the filtered protein is directly toxic to the tubular epithelium and drives the tubulointerstitial fibrosis that is the final common pathway of CKD progression. The losartan is providing some RAAS blockade but the proteinuria is still 850 mg/g — that is inadequate. We need to intensify the RAAS blockade and add an SGLT2 inhibitor, which has now demonstrated independent renoprotective effects beyond glycaemic control. In TCM, the pale enlarged tooth-marked tongue with a slightly rootless centre coating tells us the Spleen and Kidney Qi are both deficient, and the Yin is beginning to be depleted as well. The deep, thready, slightly choppy pulse tells us there is Blood stasis in the renal microvasculature — which in modern terms corresponds to the glomerular endothelial dysfunction and mesangial expansion that characterise diabetic nephropathy. The Damp-turbidity — the greasy tongue coating, the oedema, the elevated uric acid — is obstructing the renal channels. We need to tonify the Spleen-Kidney Qi-Yin, resolve the Damp-turbidity, and activate the Blood to address the microvascular stasis. That is the TCM framework for slowing diabetic nephropathy progression.

TCM Diagnosis and Integrative Treatment Strategy

The TCM diagnosis established by Dr. Chen Yiping was Kidney Deficiency with Damp-Turbidity and Blood Stasis (肾虚湿浊瘀阻证), specifically Spleen-Kidney Qi-Yin Deficiency as the root with Damp-Turbidity and Blood Stasis as the branch. The corresponding Western diagnoses were diabetic nephropathy, CKD Stage 3b, and hypertension.

The treatment principle was: tonify the Spleen and benefit the Kidney; nourish Qi and Yin; resolve Damp-turbidity and activate Blood (健脾益肾，益气养阴，化湿浊活血).

Herbal prescription — Shenqi Dihuang Tang, modified: Huangqi 30g, Dangshen 15g, Shengdihuang 15g, Shudi 12g, Shanzhuyu 12g, Shanyao 15g, Fuling 15g, Zexie 12g, Mudanpi 10g, Danshen 15g, Chishao 12g, Niuxi 12g, Zhi Dahuang 6g, Baimaogen 30g, Shiwei 15g. One decoction daily, taken warm in two divided doses. Rationale: Shenqi Dihuang Tang (Astragalus and Rehmannia Decoction) tonifies Spleen-Kidney Qi and Yin simultaneously — Huangqi and Dangshen tonify the Spleen Qi and support the immune and reparative capacity of the renal tubular epithelium; Shengdihuang, Shudi, and Shanzhuyu nourish the Kidney Yin and essence; Fuling and Zexie drain Dampness through the lower jiao; Mudanpi clears Heat from the Blood. Danshen, Chishao, and Niuxi activate Blood and resolve the microvascular stasis; Zhi Dahuang (prepared rhubarb at low dose) reduces BUN and uric acid by promoting their excretion through the bowel — a classical TCM strategy for reducing uraemic toxin accumulation; Baimaogen and Shiwei reduce proteinuria through their classical action of clearing Heat from the Kidney and cooling the Blood.

Acupuncture: Primary points: Shenshu (BL 23), Pishu (BL 20), Taixi (KD 3), Sanyinjiao (SP 6), Zusanli (ST 36), Yinlingquan (SP 9), Qihai (CV 6). Supplementary points: Guanyuan (CV 4) for Kidney Yang support; Xuehai (SP 10) and Geshu (BL 17) for Blood activation; Weizhong (BL 40) for renal channel unblocking. Reinforcing method at Shenshu, Pishu, Taixi, and Zusanli; even method at remaining points; 30-minute retention; three sessions per week.

Western pharmacotherapy — optimised: RAAS blockade intensified: losartan increased to maximum dose and finerenone (non-steroidal mineralocorticoid receptor antagonist) added for additional proteinuria reduction and renoprotection. SGLT2 inhibitor added: dapagliflozin 10 mg daily — for independent renoprotective effect (DAPA-CKD trial evidence), additional blood pressure reduction, and uric acid lowering. Glycaemic management: metformin dose reviewed (reduced per eGFR); sitagliptin replaced with a GLP-1 receptor agonist for superior HbA1c reduction and cardiovascular-renal benefit. Lipid management: atorvastatin dose optimised to achieve LDL-C <1.8 mmol/L. Uric acid management: febuxostat added for hyperuricaemia — elevated uric acid is an independent risk factor for CKD progression.

Renal dietary therapy: Protein restriction: 0.6–0.8 g/kg/day of high-biological-value protein (lean meat, fish, egg white) — to reduce proteinuria-driven tubular toxicity while maintaining nutritional adequacy. Sodium restriction: <2 g/day to support blood pressure control and reduce proteinuria. Potassium and phosphorus monitoring: dietary adjustment per serial electrolyte results. TCM dietary additions: coix seed, yam, and lotus seed incorporated as Spleen-strengthening, Dampness-resolving foods consistent with the constitutional pattern. Fluid management: adequate hydration without excess; avoidance of nephrotoxic substances including NSAIDs, contrast agents, and herbal products with known nephrotoxicity.

Treatment Course and Outcomes

At Three Months

• Fatigue and lower limb heaviness improved; nocturia reduced to 1–2 times; appetite improved; oedema resolved
• eGFR 39 mL/min/1.73m² (stable); UPCR reduced to 580 mg/g; blood pressure 132/82 mmHg — approaching target
• HbA1c improved to 7.1%; uric acid reduced to 380 μmol/L

At Twelve Months

• Symptoms essentially resolved; energy levels significantly improved; lumbar soreness reduced; nocturia once nightly
• eGFR 41 mL/min/1.73m² — improvement of 3 mL/min from baseline; UPCR reduced to 320 mg/g — 62% reduction from baseline; blood pressure consistently 128–135/78–85 mmHg at target
• HbA1c 6.9%; LDL-C 1.6 mmol/L; uric acid 340 μmol/L — all metabolic targets achieved

Three-Year Follow-Up

• eGFR 36 mL/min/1.73m² — a decline of only 2 mL/min over two years following the twelve-month stabilisation, compared with the pre-treatment rate of approximately 7 mL/min per year
• UPCR 280 mg/g — sustained proteinuria reduction
• Patient remains dialysis-free; quality of life significantly improved; patient highly satisfied with the preservation of renal function

Dr. Chen's clinical reflection: The eGFR improvement at twelve months — from 38 to 41 — is modest in absolute terms, but it represents a reversal of a trajectory that had been declining at 7 mL/min per year for three years. Stopping that decline and producing even a small improvement required every element of the programme working together: the SGLT2 inhibitor and the intensified RAAS blockade reducing the haemodynamic and inflammatory drivers of proteinuria; the herbal formula addressing the Damp-turbidity and Blood stasis that were obstructing the renal microvasculature; the dietary protein restriction reducing the tubular toxicity of the filtered protein; and the acupuncture supporting the Spleen-Kidney Qi-Yin recovery that underpins the constitutional capacity for renal repair. The three-year trajectory — a decline of 2 mL/min over two years rather than the projected 14 mL/min — is the outcome that matters. This patient came to us expecting dialysis within four years. Three years later, he is still dialysis-free, working in his garden, and sleeping through the night.

Expert Commentary — Dr. Chen Yiping

1. Proteinuria as Both Marker and Mediator: The TCM-Western Convergence in CKD Progression

The central insight that unifies the TCM and Western approaches to diabetic nephropathy management is the recognition that proteinuria is not merely a marker of renal injury but an active mediator of progressive renal damage. In modern nephrology, filtered protein — particularly albumin — is directly toxic to the proximal tubular epithelium: it activates NF-κB signalling, stimulates the production of pro-inflammatory cytokines and chemokines, and drives the tubulointerstitial fibrosis that is the final common pathway of CKD progression regardless of the initial aetiology. Reducing proteinuria is therefore not simply a surrogate endpoint — it is a direct therapeutic intervention against the mechanism of progression. In TCM, the persistent leakage of protein through the glomerular filtration barrier is understood as a failure of the Kidney to consolidate and retain the Jing — the essential substance — within the body. The Kidney Qi deficiency that allows the Jing to leak corresponds to the glomerular podocyte dysfunction and filtration barrier disruption that allows albumin to pass into the tubular lumen. Tonifying the Kidney Qi with Huangqi, Shanzhuyu, and Wuweizi — herbs that have demonstrated podocyte-protective and filtration barrier-stabilising effects in modern pharmacological studies — addresses the same pathological process from the constitutional direction that RAAS blockade addresses from the haemodynamic direction. The combination produces proteinuria reduction that neither approach achieves alone.

2. The SGLT2 Inhibitor and TCM Damp-Turbidity Resolution: Convergent Mechanisms in Renal Protection

The emergence of SGLT2 inhibitors as renoprotective agents — demonstrated in the DAPA-CKD, CREDENCE, and EMPA-KIDNEY trials to reduce the risk of CKD progression and dialysis initiation by 30–40% independent of glycaemic control — represents one of the most significant advances in nephrology of the past decade. The mechanisms of SGLT2 inhibitor renoprotection are multiple and partially understood: tubuloglomerular feedback restoration reducing intraglomerular hypertension; reduction of proximal tubular oxygen consumption reducing tubular hypoxia; anti-inflammatory and anti-fibrotic effects through NLRP3 inflammasome inhibition; uric acid lowering; and modest blood pressure reduction. In TCM terms, several of these mechanisms correspond to the action of resolving Damp-turbidity and reducing the metabolic waste accumulation — elevated uric acid, uraemic toxins, and inflammatory mediators — that obstructs the renal channels and drives progressive injury. The combination of SGLT2 inhibitor-mediated Damp-turbidity resolution from the Western pharmacological direction and herbal Damp-resolving therapy (Fuling, Zexie, Zhi Dahuang, Baimaogen) from the TCM constitutional direction produced a synergistic reduction in the metabolic and inflammatory burden on the kidney that contributed to the proteinuria reduction and eGFR stabilisation observed in this patient.

3. Dietary Protein Restriction in CKD: Aligning TCM Spleen-Kidney Dietary Therapy with Modern Renal Nutrition

Dietary protein restriction in CKD — targeting 0.6–0.8 g/kg/day of high-biological-value protein — is one of the most evidence-supported non-pharmacological interventions for slowing CKD progression, yet one of the most difficult to implement in clinical practice because it requires sustained dietary behaviour change in patients who are often asymptomatic until late-stage disease. In TCM, the dietary guidance for Spleen-Kidney deficiency patterns in CKD aligns with modern renal nutrition principles in several important respects: the emphasis on easily digestible, Spleen-nourishing foods — congee, yam, coix seed, lotus seed — corresponds to the modern recommendation for high-biological-value protein sources that are efficiently utilised and produce less uraemic waste per gram of protein consumed; the avoidance of heavy, greasy, and difficult-to-digest foods corresponds to the modern recommendation to reduce dietary phosphorus and saturated fat; and the emphasis on adequate hydration without excess corresponds to the modern recommendation for fluid management in CKD. The integration of TCM dietary principles with modern renal nutrition guidelines produces a dietary framework that is both constitutionally appropriate for the patient's TCM pattern and evidence-based from the nephrology perspective — and that is more likely to be sustained because it is grounded in a coherent explanatory framework that the patient can understand and apply independently.

How CMCS Shanghai Coordinated This Case

CMCS Shanghai supported Mr. Carmichael and his family from initial consultation through three-year follow-up, including: priority appointment coordination with Dr. Chen Yiping at Longhua Hospital with bilingual review of all prior nephrology records, eGFR trajectory data, and medication history from Australia; bilingual interpretation throughout all TCM four-examination consultations, integrative treatment planning discussions, and Western pharmacotherapy review sessions; coordination of renal function panel, urine studies, HbA1c, lipid panel, uric acid, and 24-hour ambulatory blood pressure monitoring with bilingual results communication and clinical summary for the patient's nephrologist in Australia; bilingual pharmacy support for herbal decoction preparation and concurrent medication schedule with herb-drug interaction review; structured renal dietary therapy coordination — bilingual dietary assessment, protein restriction guidance, and written dietary plan provided in English; quarterly renal function and proteinuria monitoring with bilingual trend analysis communicated to the patient's overseas nephrologist; and annual comprehensive renal summary provided to the patient's GP and nephrologist in Australia for continuity of care and dialysis planning deferral documentation.

For international patients with CKD, diabetic nephropathy, proteinuria, or other renal conditions seeking integrative TCM nephrology care in Shanghai, Dr. Chen Yiping's team at Longhua Hospital offers a clinically rigorous, evidence-informed approach — combining classical Spleen-Kidney tonification, Damp-turbidity resolution, optimised Western renal pharmacotherapy, and structured dietary therapy to slow CKD progression and preserve renal function. CMCS ensures that expertise is accessible: in the patient's language, with overseas physicians informed at every step, from the first integrative consultation through long-term follow-up.

This case report is de-identified and published for educational purposes. All clinical details have been anonymized in accordance with patient privacy standards. CMCS Shanghai is a medical concierge service and does not provide direct medical care.